Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive

Oncology·MeSH: Leukemia, Myeloid, Accelerated Phase

10 drugs in development·3 companies·2 clinical trials

Drug Pipeline by Phase

Phase 3(6)

Drug	Company
Blinatumomab	Assertio Holdings, Inc. (ASRT)
Cytarabine	Assertio Holdings, Inc. (ASRT)
Filgrastim	Assertio Holdings, Inc. (ASRT)
Liposome-encapsulated Daunorubicin-Cytarabine	Assertio Holdings, Inc. (ASRT)
Ponatinib	ENANTA PHARMACEUTICALS INC (ENTA)
Vincristine	Assertio Holdings, Inc. (ASRT)

Phase 2(2)

Drug	Company
Pegfilgrastim	Assertio Holdings, Inc. (ASRT)
Ponatinib	Assertio Holdings, Inc. (ASRT)

Phase 1(2)

Drug	Company
Cytarabine	Structure Therapeutics Inc. (GPCR)
Vincristine	Structure Therapeutics Inc. (GPCR)

BioSniper tracks 10 drugs in development for Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive across 3 companies.

There are 2 clinical trials targeting Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive tracked by BioSniper.

Full trial data, competitive analysis, and AI-powered pipeline tracking.